BACKGROUND: Infantile Pompe disease (glycogen storage disease type 2) is a fatal disorder caused by deficiency of acid alpha-glucosidase. This deficiency results in glycogen accumulation in the lysosomes of many tissues including cardiac muscle. The disease is characterized by profound hypotonia, poor growth, organomegaly, and cardiomegaly. Severe hypertrophic cardiomyopathy often is present in early infancy, and most patients die of cardiac or respiratory failure in the first year of life. This report describes the cardiac response of infants with Pompe disease to a phase 2 trial of enzyme replacement therapy (ERT). METHODS: Eight patients with classical infantile Pompe disease were given intravenous recombinant human GAA (rhGAA) for 1 year. Cardiac monitoring included echocardiography, electrocardiograms (ECGs), chest radiographs, and clinical cardiac evaluation at 4, 8, 12, 24, 36, and 52 weeks. At 52 weeks, 6 patients were alive. RESULTS: Most of the treated patients had rapid regression of ventricular hypertrophy in response to ERT, with near normalization of posterior wall thickness, ventricular mass, and ventricular size. Systolic ventricular function was preserved despite rapid changes in ventricular mass and size. Concomitantly, ECGs documented lengthening of the PR interval and decreased ventricular voltages, whereas chest radiographs documented a decreased cardiothoracic ratio. Symptoms of pulmonary congestion were diminished, and survival was improved. CONCLUSION: The cardiovascular system responds quickly and strikingly to ERT with rhGAA, suggesting rapid reversal of excessive glycogen storage in cardiac muscle cells. Changes in ventricular mass and function are maintained throughout 1 year of follow-up evaluation and associated with decreased morbidity and prolonged survival.
BACKGROUND: Infantile Pompe disease (glycogen storage disease type 2) is a fatal disorder caused by deficiency of acid alpha-glucosidase. This deficiency results in glycogen accumulation in the lysosomes of many tissues including cardiac muscle. The disease is characterized by profound hypotonia, poor growth, organomegaly, and cardiomegaly. Severe hypertrophic cardiomyopathy often is present in early infancy, and most patients die of cardiac or respiratory failure in the first year of life. This report describes the cardiac response of infants with Pompe disease to a phase 2 trial of enzyme replacement therapy (ERT). METHODS: Eight patients with classical infantile Pompe disease were given intravenous recombinant humanGAA (rhGAA) for 1 year. Cardiac monitoring included echocardiography, electrocardiograms (ECGs), chest radiographs, and clinical cardiac evaluation at 4, 8, 12, 24, 36, and 52 weeks. At 52 weeks, 6 patients were alive. RESULTS: Most of the treated patients had rapid regression of ventricular hypertrophy in response to ERT, with near normalization of posterior wall thickness, ventricular mass, and ventricular size. Systolic ventricular function was preserved despite rapid changes in ventricular mass and size. Concomitantly, ECGs documented lengthening of the PR interval and decreased ventricular voltages, whereas chest radiographs documented a decreased cardiothoracic ratio. Symptoms of pulmonary congestion were diminished, and survival was improved. CONCLUSION: The cardiovascular system responds quickly and strikingly to ERT with rhGAA, suggesting rapid reversal of excessive glycogen storage in cardiac muscle cells. Changes in ventricular mass and function are maintained throughout 1 year of follow-up evaluation and associated with decreased morbidity and prolonged survival.
Authors: Priya Sunil Kishnani; Marc Nicolino; Thomas Voit; R Curtis Rogers; Anne Chun-Hui Tsai; John Waterson; Gail E Herman; Andreas Amalfitano; Beth L Thurberg; Susan Richards; Mark Davison; Deyanira Corzo; Y T Chen Journal: J Pediatr Date: 2006-07 Impact factor: 4.406
Authors: N Raben; M Danon; A L Gilbert; S Dwivedi; B Collins; B L Thurberg; R J Mattaliano; K Nagaraju; P H Plotz Journal: Mol Genet Metab Date: 2003 Sep-Oct Impact factor: 4.797
Authors: Hannerieke M P van den Hout; Wim Hop; Otto P van Diggelen; Jan A M Smeitink; G Peter A Smit; Bwee-Tien T Poll-The; Henk D Bakker; M Christa B Loonen; Johannis B C de Klerk; Arnold J J Reuser; Ans T van der Ploeg Journal: Pediatrics Date: 2003-08 Impact factor: 7.124
Authors: Johanna M P Van den Hout; Joep H J Kamphoven; Léon P F Winkel; Willem F M Arts; Johannes B C De Klerk; M Christa B Loonen; Arnold G Vulto; Adri Cromme-Dijkhuis; Nynke Weisglas-Kuperus; Wim Hop; Hans Van Hirtum; Otto P Van Diggelen; Marijke Boer; Marian A Kroos; Pieter A Van Doorn; Edwin Van der Voort; Barbara Sibbles; Emiel J J M Van Corven; Just P J Brakenhoff; Johan Van Hove; Jan A M Smeitink; Gerard de Jong; Arnold J J Reuser; Ans T Van der Ploeg Journal: Pediatrics Date: 2004-05 Impact factor: 7.124
Authors: Richard J Ing; D Ryan Cook; Resai A Bengur; Eric A Williams; John Eck; Guy de L Dear; Allison K Ross; Frank H Kern; Priya S Kishnani Journal: Paediatr Anaesth Date: 2004-06 Impact factor: 2.556
Authors: A Amalfitano; A R Bengur; R P Morse; J M Majure; L E Case; D L Veerling; J Mackey; P Kishnani; W Smith; A McVie-Wylie; J A Sullivan; G E Hoganson; J A Phillips; G B Schaefer; J Charrow; R E Ware; E H Bossen; Y T Chen Journal: Genet Med Date: 2001 Mar-Apr Impact factor: 8.822
Authors: Piers C A Barker; Sara K Pasquali; Stephen Darty; Richard J Ing; Jennifer S Li; Raymond J Kim; Stephanie DeArmey; Priya S Kishnani; Michael J Campbell Journal: Mol Genet Metab Date: 2010-07-23 Impact factor: 4.797
Authors: Daniel A Morris; Daniela Blaschke; Alice Krebs; Sima Canaan-Kühl; Ursula Plöckinger; Gesine Knobloch; Thula C Walter; York Kühnle; Leif-Hendrik Boldt; Elisabeth Kraigher-Krainer; Burkert Pieske; Wilhelm Haverkamp Journal: Int J Cardiovasc Imaging Date: 2015-03-06 Impact factor: 2.357
Authors: Joseph W Foley; Scott D Bercury; Patrick Finn; Seng H Cheng; Ronald K Scheule; Robin J Ziegler Journal: Mol Ther Date: 2010-06-15 Impact factor: 11.454